Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

36results about How to "Implement early treatment" patented technology

In-situ hybridization testing kit of ALDH1 gene and testing method and application thereof

The invention relates to an in-situ hybridization testing kit of an aldehyde dehydrogenase (ALDH1) gene. The kit comprises a hybridization probe and a marker, wherein the sequence of the hybridization probe is shown as SEQ ID No. 1. The invention also provides an in-situ hybridization testing method of the ALDH1gene. In addition, the invention also provides application of the kit to preparation of medicaments for testing breast cancer or prognostic diseases of breast cancer. The kit provided by the invention has the characteristics of high flexibility and specificity. The testing method of the invention is convenient and easy to operate and can be generally used and popularized in district-level or city-level hospitals.
Owner:SUZHOU FUYING GENE TECH

In-situ hybridization detection kit for MICRORNA (MICRO Ribonucleic Acid)-145 level at pathologic evolution early stages of various colon cancers as well as microRNA-145 in-situ hybridization detection method and application of microRNA-145 to preparation of in-situ hybridization detection kit for colon cancers

The invention discloses an in-situ hybridization detection kit, which comprises a hybridization probe and a marker. The invention also discloses a method for detecting microRNA (micro Ribonucleic Acid)-145 which is closely correlated with the pathologic evolution at an early stage of colon cancer by using in-situ hybridization through the in-situ hybridization detection kit. The method comprises the following steps of: firstly, under the condition that the hybridization probe and a target sequence can form a stable hybrid complex, contacting RNA to be detected in a substrate with the hybridization probe to form a hybrid complex; and secondly, detecting the hybrid complex. According to the in-situ hybridization detection kit and the detection method disclosed by the invention, the expression of microRNA-145 can be detected in the RNA level, which is earlier than imaging medicine and traditional clinical biochemical detection index and the real RNA level screening at the early stage of canceration can be realized; and meanwhile, the detection method disclosed by the invention is simple and convenient, is low in cost and is convenience for popularization and application to county and district level hospitals.
Owner:SUZHOU FUYING GENE TECH

In-situ hybridization detection kit for MICRORNA (MICRO Ribonucleic Acid)-233 level at pathologic evolution early stage of colon cancer as well as microRNA-233 in-situ hybridization detection method and application of microRNA-233 to preparation of in-situ hybridization detection kit for colon cancer

The invention discloses an in-situ hybridization detection kit, which comprises a hybridization probe and a marker. The invention also discloses a method for detecting microRNA (micro Ribonucleic Acid)-233 which is closely correlated with the pathologic evolution at an early stage of colon cancer by using in-situ hybridization through the in-situ hybridization detection kit. The method comprises the following steps of: firstly, under the condition that the hybridization probe and a target sequence can form a stable hybrid complex, contacting RNA to be detected in a substrate with the hybridization probe to form a hybrid complex; and secondly, detecting the hybrid complex. According to the in-situ hybridization detection kit and the detection method disclosed by the invention, the expression of microRNA-233 can be detected in the RNA level, which is earlier than imaging medicine and traditional clinical biochemical detection index and the real RNA level screening at the early stage of canceration can be realized; and meanwhile, the detection method disclosed by the invention is simple and convenient, is low in cost and is convenience for popularization and application to county and district level hospitals.
Owner:SUZHOU FUYING GENE TECH

Horizontal in-situ hybridization detection kit and detection method as well as application for MICRORNA17-3P in earlier stage of cancer pathologic evolution

The invention discloses an in-situ hybridization detection kit which comprises a hybridization probe and a marker. The invention also discloses an in-situ hybridization detection method for microRNA-17-3p being closely related to the early pathologic evolution of various cancers by using the kit. The in-situ hybridization detection method comprises the following steps of: (1) under the condition that the hybridization probe and a target sequence can form a stable hybridization complex, leading RNA (Ribonucleic Acid) to be tested in a substrate to be in contact with the hybridization probe, and forming the hybridization complex; and (2) detecting the hybridization complex. The kit and the detection method provided by the invention can be used for detecting the expression quantity of the microRNA17-3p at the level of RNA, which is more early obtained in comparison with detection indexes of imaging medicine and the traditional clinical biochemistry, thereby the RNA level screening can be realized truly in the earlier stage of canceration, and simultaneously, the detection method provided by the invention is simple and convenient and low in cost and is convenient to popularize and apply in county-level hospitals.
Owner:SUZHOU FUYING GENE TECH

Horizontal in-situ hybridization detection kit and detection method as well as application for MICRORNA-143 in earlier stage of cancer pathologic evolution

The invention discloses an in-situ hybridization detection kit which comprises a hybridization probe and a marker. The invention also discloses an in-situ hybridization detection method for microRNA-143 being closely related to the early pathologic evolution of various cancers by using the kit. The in-situ hybridization detection method comprises the following steps of: (1) under the condition that the hybridization probe and a target sequence can form a stable hybridization complex, leading RNA (Ribonucleic Acid) to be tested in a substrate to be in contact with the hybridization probe, and forming the hybridization complex; and (2) detecting the hybridization complex. The kit and the detection method provided by the invention can be used for detecting the expression quantity of the microRNA17-143 at the level of RNA, which is more early obtained in comparison with detection indexes of imaging medicine and the traditional clinical biochemistry, thereby the RNA level screening can be realized truly in the earlier stage of canceration, and simultaneously, the detection method provided by the invention is simple and convenient and low in cost and is convenient to popularize and apply in county-level hospitals.
Owner:SUZHOU FUYING GENE TECH

MRNA level in-situ hybridization detection kit of KLF4 gene in earlier stage of pathologic evolution of human cardiovascular and cerebtovascular disease, detection method and application

The invention discloses an in-situ hybridization detection kit which comprises a hybridization probe and a marker. The invention also discloses a method for in-situ hybridization detection of vascular endothelial cell's genetic factor (KLF4) gene's mRNA which is closely related with pathologic evolution of cardiovascular and cerebtovascular vascular endothelial injury in the earlier stage by the use of the kit. The method comprises the following steps: (1) under the condition that a hybridization probe and a target sequence can form a stable hybrid complex, RNA to be tested in a substrate is contacted with the hybridization probe so as to form a hybrid complex; and (2) the hybrid complex is detected. According to the detection kit and the detection method, gene expression quantity can be detected at the RNA level, the index of the detection method is ealier than present clinical biochemical detection index (protein detection index), and genuine RNA level screening of the earlier stage of cardiovascular and cerebtovascular disease can be realized. Meanwhile, the detection method provided by the invention is simple and convenient; cost is low; and the method is convenient for popularization and application in district-level hospitals.
Owner:嘉兴瑞康生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products